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ABSTRACT
Objective To determine how the risk of HIV transmission
from homosexual men receiving antiretroviral treatment
is related to patterns of patient monitoring and condom
use.
Methods A stochastic mathematical simulation model
was developed of cohorts of men in the Netherlands
who have sex with men (MSM), deﬁning the parameters
of the model using observational cohort data. The model
incorporates viral load trends during ﬁrst-line treatment,
patient monitoring and different scenarios for the way in
which condom use may depend on recent viral load
measurements. The model does not include the effect of
sexually transmitted infections on HIV transmission.
Results For MSM receiving treatment, the risk of
transmitting HIV to their long-term partner is 22%
(uncertainty interval: 9e37%) if condoms are never
used. With incomplete use (in 30% of sex acts) the risk
is reduced slightly, to 17% (7e29%). However, the risk
is as low as 3% (0.2e8%) when men receiving
treatment use condoms only 6 months beyond their last
undetectable viral load measurement. The risk is further
reduced when 3 months is the time period beyond which
condoms are used.
Conclusions When condom use by HIV-infected men
receiving combination treatment with antiretroviral
agents is based on their last viral load measurement, the
transmission risk is much lower than with incomplete
condom use. The key message for patients is that
although always using condoms during treatment is the
best way to protect partners from the risk of HIV
transmission, when such use cannot be achieved, the
second best strategy is to use condoms whenever the
last undetectable viral load was measured more than
3 months ago.
INTRODUCTION
Since the mid-1990s, people infected with HIV in
industrialised countries have been able to access
combination antiretroviral treatment (cART),
1 2
which has substantially decreased HIV-associated
mortality in these populations.
3 More recently, this
trend has been repeated in many developing coun-
tries, along with signs of decreasing HIV mortality.
4
In both settings, there is a trend for earlier initiation
of treatment
5 and increasing debate about whether
starting treatment earlier (or even immediately on
HIV diagnosis) is advisable in order to improve
clinical outcomes and reduce HIV transmission.
67
As the population receiving treatment grows its
potential contribution to HIV epidemic increases.
Therefore,weexpectthat theinfectiousness andthe
sexual behaviour of those receiving treatment will
become key determinants of the trajectory of the
global epidemic in the coming years.
The rate of HIV transmission from infected
people is closely tied to their plasma viral load,
which cARTcan reduce to very low levels.
8 On this
evidence, in 2008 the Swiss National AIDS
Commission (EKAF) suggested that there was
effectively no risk of sexual transmission from
patients receiving cART, provided that they (i)
follow the guidelines for antiretroviral treatment
strictly, (ii) have no detectable viral load when
measured in the past 6 months and (iii) have no
other sexually transmitted infection (STI).
91 0The
implication that such patients need not use
condoms with their sexual partners was warmly
welcomed by patient groups and activists.
11
In response, many argued that this was not
a helpful public health message. Although the
chance of transmission from men receiving treat-
ment is likely to be low, it is unlikely to be zero,
since at least one transmission event from a man
receiving successful cART has occurred,
12 and over
many sex acts among many men, a small rate of
transmission could translate into a large number of
new infections.
13 14 A simple model was used to
argue this point,
13 but it did not estimate the
absolute risk of transmission from men receiving
treatment; nor did it account for condom use being
conditional on a recent viral load measurement, as
the EKAF statement recommended.
9
In this paper, using uniquely detailed data on the
trends in viral loads among men receiving treat-
ment
17 and a new stochastic mathematical model,
we estimate the risk of HIV transmission from men
in the Netherlands who have sex with men (MSM)
and determine how this is inﬂuenced by various
patterns of condom use (including those based on
the Swiss recommendations) and schedules of viral
load monitoring.
METHODS
Following earlier work,
18 19 we developed
a stochastic individual-based simulation model of
viral load trends, HIV transmission risk and patient
monitoring among cohorts of MSM in the
Netherlands. The vast range of possibilities for the
evolution of viral load over time was conceptualised
as three distinct trajectories (ﬁgure 1). Data from
the ATHENA observational cohort of HIV-infected
individuals in the Netherlands
17 were used to
evaluate the parameters (table 1, with further detail
provided in the online technical appendix).
The risk of transmission is characterised as the
probability that a man receiving treatment will
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Epidemiologyinfect his uninfected sexual partner over the course of ﬁrst-line
treatment. We examined only the special case where a partner-
ship is maintained over the entire duration of ﬁrst-line treatment
and did not include the effect of STIs on the chance of HIV
transmission. In most analyses, the functional relationship
between plasma viral load and the chance of transmission in
each unprotected sex act was based on a Hill function ﬁtted
to observational data on HIV transmission in Zambia by Fraser
et al.
20 This function is supported by recent review of trans-
mission rates
15 16 and is denoted the ‘Fraser et al’ assumption.
The function was rescaled to match the observed approximate
transmission risk for each sex act for MSM (w0.01 for men with
log-viral loads of w4.5 log-copies)
13 (supplementary ﬁgure S2).
An alternative assumption for the relationship (linear trend in
log-risk and log-viral load
21: see ﬁgure S2) was used as well in
sensitivity analyses: this is denoted the ‘Wilson et al’ assump-
tion. We assumed that there were 100 sex acts a year in the
partnership and that the efﬁcacy of condoms in reducing
transmission is 95%. In uncertainty analyses, the model
assumption for which there was least directly relevant data was
varied independently in a Monte Carlo analysis: speciﬁcally, the
frequency of sex acts per years (uniform between 50 and 150),
the efﬁcacy of condoms when used (uniform between 85% and
100%) and chance of transmission per sex act without treatment
(uniform from 0.0075 to 0.0125). A combined 95% uncertainty
interval (the range between the 2.5th and 97.5th centiles of the
resultant distribution) was calculated.
In the model, reﬂecting clinical guidelines,
22 patients with
undetectable viral loads are monitored every 4 months. When
viral load is detectable, the patient returns for another
appointment after 8 weeks and the treatment regimen is then
changed if retesting conﬁrms the ﬁnding.
Various scenarios for condom use in partnerships were
considered: (i) never using condoms; (ii) using condoms in 30%
of sex acts
24; (iii) not using condoms if viral load was un-
detectable at the last measurement in the past 6 months; and,
(iv) always using condoms. Scenario (iii) corresponds to the way
that the EKAF statement has been interpreted and we consid-
ered two variants whereby the decision not to use condoms is
based on the last measurement in the past 3 months (instead of
6 months) or the last viral load measurement ever taken (ie,
irrespective of time).
RESULTS
We found that men receiving treatment pose a substantial risk of
HIV transmission (22% (9e37% in uncertainty analysis)) to
their partners if they do not use condoms (ﬁgure 2), and the
relationship between viral load and transmission is as described
by Fraser et al.
20 This risk is generated in three ways: (i) treat-
ment is not sufﬁcient to suppress viral load, so transmission can
occur even if the regimen is quickly changed; (ii) the level of
virus can rebound quickly and reach high levels before detection
and change of regimen; (iii) even with suppressed viral loads, the
risk of transmission is not zero, so that over the many sex acts
during treatment, the cumulative chance of transmission
becomes non-negligible.
Using condoms 30% of the time reduces the chance of
transmission but only marginally (to 17% (7e29% in
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Figure 1 Schematic representation of the three assumed trajectories
of (log) viral load after treatment initiation: (i) suppression achieved and
adherence good (dotted line); (ii) suppression achieved but adherence
poor (solid line); and (iii) suppression not achieved (dashed line). The
circles indicate when the regimen was changed. Parameter values are
presented in table 1 and details are provided in the online supplementary
appendix.
Table 1 Natural history parameters for HIV infection receiving ﬁrst-line treatment (Source: ATHENA cohort data
17) Refer to the technical appendix for
details
Parameter Value Unit
Log10 viral load at treatment initiation (normal distribution) Mean 5.1 Log copies per microlitre
Variance 0.40
Fraction achieving suppression* 0.70 Fraction
Fraction with good adherencey 0.94 Fraction
Waiting time until viral suppression, if suppression and good adherence (exponential distribution) Median 5.38 Months
Waiting time until viral suppression, if suppression and not good adherence (exponential distribution) Median 5.92 Months
Waiting time (months) until viral rebound, if good adherence (double Weibull distribution), assuming
shortened (s) survival times (used unless otherwise stated) or extended (e) survival.
Shape1 1.14 (e) 10.23 (s) Months
Scale1 456.65 (e) 153.25 (s)
Shape2 1.92 (e) 1.25 (s)
Scale2 20.70 (e) 41.58 (s)
Weighting 0.91 (e) 0.77 (s)
Waiting time until viral rebound, if not good adherence (Weibull distribution) Shape1 1.14 Months
Scale1 132.86
Rate of increase in log10 viral load on rebound, if good adherencez Rate 0.07 (se¼0.002) Log10 copies per microlitre per month
Rate of increase in log10 viral load on rebound, if not good adherencez Rate 0.16 (se¼0.01) Log10 copies per microlitre per month
Maximum survival time with non-suppressed viral load Max 1 Years
Log10 viral load if no suppression (normal distribution) Mean 3.80 Log copies per microlitre
Variance 0.84
*Suppression is deﬁned as at least two consecutive viral load measurements <500 HIV RNA copies per millilitre.
yAdherence is classiﬁed as good or poor based on the measurement of plasma drug levels.
zAt all times in the simulation, viral load is limited to less than or equal to the 95th centile of viral loads at treatment initiation in the ATHENA data (equal to six log-copies).
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Epidemiologyuncertainty analysis)), since there remains a substantial
numbers of unprotected sex acts overall. In contrast, men who
always use condoms unless their viral load was undetectable at
the last measurement in the past 6 months are much less likely
to transmit HIV to their partner (chance of transmission: 3%
(0.2e8% in uncertainty analyses)). This is because the risk
generated in the ﬁrst two ways has been largely removed. Men
following this strategy, on average, use condoms 10% of the
time they are receiving treatment, while reducing the risk of
transmission to 3%. The risk with this strategy is nevertheless
greater than always using condoms, in which the chance is 1%
(0e7% in uncertainty analysis) (ﬁgure 2). The risk is not zero,
because condom efﬁcacy is not perfect.
Using the alternative (‘Wilson et al’) assumption about the
relationship between plasma viral load and transmissibility, the
overall chance of infection if condoms are not used is higher
(47% vs 22%), but the same key result is reproduced: men who
use condoms unless their viral load was undetectable in the past
6 months are much less likely to transmit HIV to their partner
than if condoms are used intermittently (online ﬁgure S3).
The frequency with which patients receiving treatment are
monitored is a key determinant of the chance of HIV trans-
mission (ﬁgure 3A). Patients monitored frequently can be quickly
switched to new regimens if ﬁrst-line treatment failsdthat is,
before viral load increases and they have exposed their partner to
an increased risk of transmission for a long period. The second
effect of increased frequency of monitoring is the reduction in
overall condom use. This is because with less frequent moni-
toring, many men with suppressed viral loads would use
condoms since they have not had a recent viral load measure-
ment. With monitoring every 18 months, condoms would be
used in w70% of sex acts, but with monitoring every 3 months,
condoms are used in only 9%.
The beneﬁt of patient monitoring is inﬂuenced by the
proportion of patients lost to follow-up. The probability of
infecting a partner increases from 2% when none of the patients
are lost to follow-up, to 5% when 20% do not return for care
(ﬁgure 3B). This is because increases in viral load go undetected
for longer, exposing partners to a higher risk of infection.
Finally, we examined three ways in which condom use could
be based on viral load measurements (online ﬁgure S5). The
decision not to use condoms could be based on an undetectable
viral load in the past 3 months, the past 6 months or the last
measurement ever. With the decision based on a measurement in
the past 3 months, there is reduced transmission compared with
a decision based on the past 6 months, provided that patients are
monitored at least every 3e12 months. However, with the
decision based only on the last measurement regardless of time,
the chance of transmission is higher, especially if monitoring
intervals are longer.
DISCUSSION
The debate about the EKAF statement on HIV transmission from
patients receiving cART
13 and earlier modelling work
14 did not
consider the way in which deciding not to use condoms might be
conditional on the last viral load measurement. There was also
little focus on estimating the rate of HIV transmission across the
population or exploring how it is inﬂuenced by patterns of
patient monitoring. In this paper we have shown that basing the
decision to use condoms on viral load provides substantially
better protection to partners than incomplete condom use,
provided that the measurement is within the past 3e6 months.
Compared with always using condoms, the viral-load-dependent
strategy allows slightly more HIV transmission (2e3% vs 1%).
However, as condoms are needed much less of the time (10% vs
100%), adherence to this strategy may be better.
Our results also highlight the importance of monitoring
patients more often and minimising losses to follow-up.
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Figure 2 Probability of transmission to partner during ﬁrst-line
treatment, if condoms are never used; condoms are used 30% of the
time; (iii) condoms are used unless last viral load (VL) measurement in
the past 6 months was undetectable; or always using condoms. Error-
bars show the 95% uncertainty interval, as described in the text. It is
assumed that the partnership is maintained over the entire course of
ﬁrst-line treatment and that viral load is related to transmission rate, as
Fraser et al
20 have described.
Figure 3 The inﬂuence of (A) monitoring frequency and (B) loss to
follow-up on the probability of HIV transmission, assuming condoms are
used unless last viral load measurement in the past 6 months was
undetectable. It is assumed that the partnership is maintained over the
entire course of ﬁrst-line treatment and that viral load is related to
transmission rate, as Fraser et al
20 have described.
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EpidemiologyWithout such effort, increases in viral load go undetected,
exposing partners to higher risks of transmission.
23 With
measurement at intervals of 3e12 months, the risk of trans-
mission can be reduced further by basing condom use on
measurements taken only 3 months before. This guards against
the risk of increases in viral load since the last measurement.
25
For this reasons, it is important that decisions are not based on
viral load measurements taken more than 6 months before.
The model used in this paper incorporates more biological
realism than earlier work
13 14 by using the functional form of
the viral loadetransmission relationship that reﬂects a sophisti-
cated analysis of observational data,
20 explicitly tracking viral
load monitoring and modelling the course of viral load evolution
over time. Nevertheless, a number of simplifying assumptions
were made. The risk of transmission per sex act was scaled to
match only an approximate observation of the risk, without
considering differences in the frequency of being the insertive or
receptive partner.
26 27 We assumed that, below a certain viral
load level, the chance of transmission is low and not actually
zero; but evidence is lacking, since observing almost no instances
of transmission
15 could be consistent with either possibility. The
response of patients to treatment varies widely and we have
attempted to only broadly represent this in the model. However,
we believe the key features of viral load evolution have been
captured by ﬁnding a set of parameters for the viral load
trajectory (its rise, period of stability and subsequent rise) and its
relationship to treatment adherence. An important limitation of
the model is that the effects of other STIs on HIV transmission is
not incorporated. The data available from the cohort do not
permit a detailed representation of STI transmission and the
inﬂuence of STIs would depend on many factors, including the
pattern of STI spread across the populations. If STIs were
included, the overall estimate of HIV transmission risk would
probably be greater, but we would expect the key relationship
between risk and patterns of condom use to hold or be
strengthened (since more frequent screening affords greater
opportunityfortreatingSTIs).Finally,themodeldoesnotinclude
the inﬂuence of intermittent viraemia on the chance of HIV
transmission, since we assumed its inﬂuence on transmission to
be relatively small.
28
The implications of this work are that the key message to
patients should remain that always using condoms when
receiving treatment is the best way to protect partners from the
risk of HIV transmission. However, an additional message is that
using condoms is most crucial when patients have not recently
(within the past 3 months) had an undetectable viral load
measurement. This message reﬁnes the intuitive association
between successful treatment and reduced transmission
24 29 and
could substantially improve protection for infected partners.
This advice must be supported by frequent viral load monitoring
(at least every 6 months, but preferably every 3 months) of all
patients receiving treatment.
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